Abstract
Robot-assisted laparoscopic radical cystectomy (RARC) has emerged as a viable treatment option for patients with muscle-invasive bladder cancer and select patients with high-risk nonmuscle invasive disease. Operative, perioperative, and intermediate-term oncologic outcomes for RARC from multiple single-institution reports and from multi-institutional studies appear promising. Long-term oncologic outcomes for RARC should be forthcoming in the years ahead. As technology improves, total intracorporeal urinary diversion may become easier to perform and less time-consuming. This article aims to review the most recent developments within the past 1 to 2years surrounding RARC, important technical nuances for performing this operation, and the future direction of RARC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
